Nexalin’s Breakthrough DIFS™ Device Reduces Blood Pressure, Improves Mental Health
Nexalin Technology, Inc. announced positive results from a clinical study published in the Journal of Affective Disorders, showing its...
Tenaya Therapeutics Gets $8M Grant for Heart Failure Research
Tenaya Therapeutics received an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund its Phase...
Seclidemstat and Azacitidine Trial for Hematologic Cancers Patient Enrollment Resumes
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial at MD...
GH001 Meets Primary Endpoint in Phase 2b TRD Trial
GH Research PLC announced positive Phase 2b trial results for GH001, an inhalable mebufotenin treatment for treatment-resistant depression (TRD)....
Invivyd Announces Positive Phase 1/2 Data for VYD2311 for COVID-19
Invivyd announced positive Phase 1/2 clinical trial data for VYD2311, a monoclonal antibody designed to offer superior, long-lasting protection...
Eyonis™ Lung Cancer Screening Meets Primary Endpoint in RELIVE Trial
Median Technologies announced positive top-line results from its RELIVE study for eyonis™ LCS, an AI-powered lung cancer screening software....
PrecivityAD2™ Blood Test Improves Alzheimer’s Disease Evaluation
Researchers found that C2N Diagnostics‘ PrecivityAD2 blood test improved healthcare providers’ ability to assess the likelihood of Alzheimer’s diseaseAlzheimer’s...
Eli Lilly’s Omvoh gets FDA approval for Crohn’s disease but faces challenges
Eli Lilly’s Omvoh, an IL-23 inhibitor previously approved for ulcerative colitis, has received FDA approval for Crohn’sCrohn’s disease. Despite...
Datopotamab Deruxtecan Recommended for Approval in the EU
Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody drug conjugate developed by Daiichi Sankyo and AstraZeneca, has been recommended for approval...
Cervomed Neflamapimod DLB Program Update at Lewy Body Dementia Conference
CervoMed provided an update on its Phase 2b RewinD-LB trial for neflamapimod in dementia with Lewy bodies (DLB). The...